Clexio Biosciences
Tal Birnberg has a diverse work experience in the field of clinical pharmacology and personalized medicine. They are currently serving as the Head of Clinical Pharmacology at Clexio Biosciences since 2022. Prior to this, Tal worked as the Clinical Pharmacology and Personalized Medicine Manager at Neuroderm from 2017 to 2022. They also held positions at Teva Pharmaceutical Industries Ltd., starting as an Experimental Medicine Leader from 2011 to 2013 and later becoming a Personalized Medicine and Pharmacogenomics expert from 2013 to 2017. Before joining Teva Pharmaceutical Industries, Tal was a Research Coordinator at Teva Pharmaceuticals in 2010, focusing on MS & Autoimmune research.
Tal Birnberg holds a PhD in Immunology from the Weizmann Institute of Science. In addition, Tal Birnberg has obtained a certification from Jolt.io in 2020.
This person is not in any offices
Clexio Biosciences
Clexio Biosciences is a CNS-first clinical-stage pharmaceutical company. Our therapies are designed to address patients’ unmet needs through scientifically based integration of drugs with innovative technologies. Clexio’s growing pipeline is focused on the development of safe and effective treatments with rapid onset of action for a wide range of neurological and psychiatric conditions, including Major Depressive Disorder, Parkinson’s Disease, Pain and other conditions involving impairment of the neurological system. Patients, and what they are living with, are at the center of everything we do. Our passion is to find ways to help patients regain a sense of balance, health and a life worth living. Clexio’s team is comprised of a multi-disciplinary team with vast experience in drug development. We see our team and our partners as the key ingredients to our success. Join our vision to make lives of millions of patients worth living again.